Combinostics

cNeuro — clinical decision support for neurodegenerative disease: a cloud platform that combines MRI and PET imaging with CSF biomarkers and neuropsychological test results into one analysis supporting Alzheimer's and MS diagnosis. VTT spin-off founded in Tampere in 2014 by Jyrki Lötjönen and Jussi Mattila, both VTT scientists in biosignal and medical image processing (Lötjönen a principal scientist and team leader there), with Lennart Thurfjell. Now part of SyntheticMR AB, listed on Nasdaq First North Stockholm, but operating under its own brand. Voima Ventures exit.

The row

Sector

Medtech & Digital Health

Stage

In market — Product is being sold

Location

Tampere

Founded

2014

Research origin

VTT

Business ID

2631684-7 · Finnish trade register

Funding

€3.9M Series A (2019), then acquired by SyntheticMR AB (Sweden) for €4.3M — agreement 28.11.2024, closed 1/2025, of which €3.93M cash and €0.37M a promissory note converting to shares. The exit price is roughly what the Series A itself raised, which is why this is not a scaler despite the acquisition

Links

Where this sits on the map

Combinostics is one of 33 companies in Medtech & Digital Health. The others:

How this row was decided

Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗